Piramal Pharma Reports Strong Q2 and H1 FY27 Revenue and Profit Growth
Piramal Pharma Limited reported strong financial results for Q2 and H1 FY27, with revenue growth of 28% and 23% year-on-year respectively, driven by all three business segments. EBITDA rose 72% in both periods, supported by improved capacity utilization, operating leverage, and cost optimization. The company added 22 new customers and completed 12 regulatory inspections without any adverse findings. Based on this performance, Piramal Pharma upgraded its FY27 revenue growth outlook to 19-20%, anticipating higher profitability.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (78/100). Lens Score 38/100.
Outlets measured: thetribune, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (78–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 28 Oct, 03:34 am. Other outlets followed.
- 1